The second A+H new energy core target after Contemporary Amperex Technology, CNGR Advanced Material (300919.SZ), has set its initial issuance range at 34.00 to 37.80 Hong Kong dollars.
Zhongwei Group's initial issue price range is set at HK$34.00 to HK$37.80.
On the morning of November 7, CNGR Advanced Material, a global leader in the field of new energy materials, disclosed the announcement on the publication of the H-share prospectus, the price range of H-share issuance, and the Hong Kong public offering. The price range of the Hong Kong stock issuance has been preliminarily set at 34.00 Hong Kong dollars to 37.80 Hong Kong dollars.
The total number of H-shares to be issued globally in this offering is 104,225,400 shares (subject to adjustments based on the exercise of the over-allotment option and the green shoe option), of which, 10,422,600 shares are preliminarily allocated for the Hong Kong public offering (subject to reallocation), accounting for approximately 10.00% of the total global offering; and 93,802,800 shares for international offering (subject to reallocation and determination based on the exercise of the over-allotment option), accounting for approximately 90.00% of the total global offering.
From the listing date to 30 days after the deadline of the Hong Kong public offering, the joint global coordinators can request the company to issue up to an additional 15,633,800 H-shares at the offering price through the exercise of the over-allotment option.
CNGR Advanced Material is the second core target on the new energy track A+H after Contemporary Amperex Technology. Its core lies in being a global leader in new energy battery materials, serving as a leading company in the field of precursor materials and cathode materials. The products of CNGR Advanced Material form the core components of lithium-ion batteries, greatly determining the performance of the batteries.
In this Hong Kong IPO, CNGR Advanced Material's industry core status, full-dimensional upgrade across the cycle, and upcoming performance recovery period resonate with the optimistic expectations of foreign investors for the industry of Shanxi Guoxin Energy Corporation.
Related Articles

SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.
SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


